5. Conclusion
Our study assessed the effects of non-adherence to edoxaban on PK and
PD. We developed an appropriate remedial dosing strategy for NVAF
patients based on the populational PK/PD model. Our simulation has shown
that current EHRA recommendations may not be the optimal remedial dosing
for patients with delayed or missed doses. Model-informed simulation is
an accessible method for effectively addressing the remedial dosing
strategy. In practice, clinicians can use our strategy and balance
patients’ thrombosis and bleeding risk to determine the optimal remedial
strategy.